Vivozon Pharmaceutical Forms Sales Partnership with Hanmi Pharmaceutical for Non-Narcotic Analgesic "Onapraju"

Targeting Mid-Sized Hospitals with Fewer Than 300 Beds

Vivozon Pharmaceutical announced on January 7 that it has signed a joint promotion partnership agreement with Hanmi Pharmaceutical for the non-narcotic analgesic "Onapraju" (ingredient: Opiranserin Hydrochloride).

Through this agreement, the two companies will collaborate on the overall distribution, sales, and marketing of Onapraju, targeting medical institutions with fewer than 300 beds as their main focus. Vivozon Pharmaceutical will supply the finished product of Onapraju, while Hanmi Pharmaceutical plans to leverage its hospital sales network to target the mid-sized hospital market.

Onapraju is a non-narcotic analgesic that was approved in December 2024 by the Ministry of Food and Drug Safety as the 38th domestically developed new drug. It blocks pain transmission in both the central and peripheral nervous systems through a dual mechanism that simultaneously inhibits glycine transporter type 2 (GlyT2) and serotonin receptor type 2A (5-HT2A). Within just two months of its launch last year, it recorded sales of 2.87 billion won.

A representative from Vivozon Pharmaceutical stated, "Through our collaboration with Hanmi Pharmaceutical, we hope to rapidly expand access to Onapraju, particularly in the mid-sized hospital market with fewer than 300 beds," adding, "Amid the growing demand in the medical field for non-narcotic analgesics, we aim to provide a treatment option with proven safety and efficacy and lead the market."

This content was produced with the assistance of AI translation services.